Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma

Benjamin Lok, Sabrina Khan, Robert Mutter, Jeffrey Liu, Ryan Fields, Melissa Pulitzer, Weiji Shi, Zhigang Zhang, Dennis Kraus, David Pfister, Klaus J. Busam, Isaac Brownell, Nancy Lee

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

BACKGROUND. The role of radiotherapy (RT) in the management of Merkel cell carcinoma (MCC) is controversial. The authors of this report evaluated the rates and patterns of failure in a selected group of patients who underwent RT for MCC of the head and neck (HN). METHODS. The records of 145 consecutive patients with MCC of the HN who presented to the authors' institution between 1988 and 2009 were reviewed. Only patients who received RT at the institution were included. The cumulative incidence of locoregional failure (LRF), distant metastatic failure (DMF), disease progression (DP) and disease-specific death (DSD) were estimated with death as a competing risk. RESULTS. Forty-eight patients were identified. The median follow-up was 51 months (range, 6-220 months) for living patients. LRF developed in 5 patients (10%), and those patients had a median time to recurrence of 3 months. Two of the 5 LRFs were local and developed at the edge of the treatment field; the remaining 3 LRFs were in lymph nodes and occurred outside the treatment field. DMF developed in 12 patients (25%). The estimated 5-year cumulative incidences of LRF, DP, and DSD were 10%, 30%, and 21%, respectively. Acute toxicities included 5 episodes (10%) of grade 3 dermatitis and 1 episode (2%) of grade 3 mucositis. CONCLUSIONS. The authors report a site-specific series of patients with HN MCC who received RT. In this group of patients with adverse features, RT was well tolerated, and LRF was low. The propensity for MCC to recur at the edge of the treatment field suggests that generous margins are appropriate when RT is administered. Cancer 2012. © 2011 American Cancer Society. Adjuvant radiotherapy may benefit patients with Merkel cell carcinoma, which is a rare aggressive neuroendocrine tumor of the skin that is prone to high rates of locoregional failure and systemic progression. The authors report a site-specific series of head and neck Merkel cell carcinoma patients who received radiotherapy and observe that radiation is well tolerated and the rate of locoregional recurrence is low.

Original languageEnglish (US)
Pages (from-to)3937-3944
Number of pages8
JournalCancer
Volume118
Issue number16
DOIs
StatePublished - Aug 15 2012
Externally publishedYes

Fingerprint

Merkel Cell Carcinoma
Neck
Radiotherapy
Head
Therapeutics
Disease Progression
Recurrence
Mucositis
Adjuvant Radiotherapy
Neuroendocrine Tumors
Incidence
Dermatitis

Keywords

  • carcinoma
  • head and neck
  • Merkel cell
  • neuroendocrine
  • radiation
  • radiotherapy
  • recurrence
  • survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lok, B., Khan, S., Mutter, R., Liu, J., Fields, R., Pulitzer, M., ... Lee, N. (2012). Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. Cancer, 118(16), 3937-3944. https://doi.org/10.1002/cncr.26738

Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. / Lok, Benjamin; Khan, Sabrina; Mutter, Robert; Liu, Jeffrey; Fields, Ryan; Pulitzer, Melissa; Shi, Weiji; Zhang, Zhigang; Kraus, Dennis; Pfister, David; Busam, Klaus J.; Brownell, Isaac; Lee, Nancy.

In: Cancer, Vol. 118, No. 16, 15.08.2012, p. 3937-3944.

Research output: Contribution to journalArticle

Lok, B, Khan, S, Mutter, R, Liu, J, Fields, R, Pulitzer, M, Shi, W, Zhang, Z, Kraus, D, Pfister, D, Busam, KJ, Brownell, I & Lee, N 2012, 'Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma', Cancer, vol. 118, no. 16, pp. 3937-3944. https://doi.org/10.1002/cncr.26738
Lok, Benjamin ; Khan, Sabrina ; Mutter, Robert ; Liu, Jeffrey ; Fields, Ryan ; Pulitzer, Melissa ; Shi, Weiji ; Zhang, Zhigang ; Kraus, Dennis ; Pfister, David ; Busam, Klaus J. ; Brownell, Isaac ; Lee, Nancy. / Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. In: Cancer. 2012 ; Vol. 118, No. 16. pp. 3937-3944.
@article{434e541cd17d468a884ef9cf300fb953,
title = "Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma",
abstract = "BACKGROUND. The role of radiotherapy (RT) in the management of Merkel cell carcinoma (MCC) is controversial. The authors of this report evaluated the rates and patterns of failure in a selected group of patients who underwent RT for MCC of the head and neck (HN). METHODS. The records of 145 consecutive patients with MCC of the HN who presented to the authors' institution between 1988 and 2009 were reviewed. Only patients who received RT at the institution were included. The cumulative incidence of locoregional failure (LRF), distant metastatic failure (DMF), disease progression (DP) and disease-specific death (DSD) were estimated with death as a competing risk. RESULTS. Forty-eight patients were identified. The median follow-up was 51 months (range, 6-220 months) for living patients. LRF developed in 5 patients (10{\%}), and those patients had a median time to recurrence of 3 months. Two of the 5 LRFs were local and developed at the edge of the treatment field; the remaining 3 LRFs were in lymph nodes and occurred outside the treatment field. DMF developed in 12 patients (25{\%}). The estimated 5-year cumulative incidences of LRF, DP, and DSD were 10{\%}, 30{\%}, and 21{\%}, respectively. Acute toxicities included 5 episodes (10{\%}) of grade 3 dermatitis and 1 episode (2{\%}) of grade 3 mucositis. CONCLUSIONS. The authors report a site-specific series of patients with HN MCC who received RT. In this group of patients with adverse features, RT was well tolerated, and LRF was low. The propensity for MCC to recur at the edge of the treatment field suggests that generous margins are appropriate when RT is administered. Cancer 2012. {\circledC} 2011 American Cancer Society. Adjuvant radiotherapy may benefit patients with Merkel cell carcinoma, which is a rare aggressive neuroendocrine tumor of the skin that is prone to high rates of locoregional failure and systemic progression. The authors report a site-specific series of head and neck Merkel cell carcinoma patients who received radiotherapy and observe that radiation is well tolerated and the rate of locoregional recurrence is low.",
keywords = "carcinoma, head and neck, Merkel cell, neuroendocrine, radiation, radiotherapy, recurrence, survival",
author = "Benjamin Lok and Sabrina Khan and Robert Mutter and Jeffrey Liu and Ryan Fields and Melissa Pulitzer and Weiji Shi and Zhigang Zhang and Dennis Kraus and David Pfister and Busam, {Klaus J.} and Isaac Brownell and Nancy Lee",
year = "2012",
month = "8",
day = "15",
doi = "10.1002/cncr.26738",
language = "English (US)",
volume = "118",
pages = "3937--3944",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "16",

}

TY - JOUR

T1 - Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma

AU - Lok, Benjamin

AU - Khan, Sabrina

AU - Mutter, Robert

AU - Liu, Jeffrey

AU - Fields, Ryan

AU - Pulitzer, Melissa

AU - Shi, Weiji

AU - Zhang, Zhigang

AU - Kraus, Dennis

AU - Pfister, David

AU - Busam, Klaus J.

AU - Brownell, Isaac

AU - Lee, Nancy

PY - 2012/8/15

Y1 - 2012/8/15

N2 - BACKGROUND. The role of radiotherapy (RT) in the management of Merkel cell carcinoma (MCC) is controversial. The authors of this report evaluated the rates and patterns of failure in a selected group of patients who underwent RT for MCC of the head and neck (HN). METHODS. The records of 145 consecutive patients with MCC of the HN who presented to the authors' institution between 1988 and 2009 were reviewed. Only patients who received RT at the institution were included. The cumulative incidence of locoregional failure (LRF), distant metastatic failure (DMF), disease progression (DP) and disease-specific death (DSD) were estimated with death as a competing risk. RESULTS. Forty-eight patients were identified. The median follow-up was 51 months (range, 6-220 months) for living patients. LRF developed in 5 patients (10%), and those patients had a median time to recurrence of 3 months. Two of the 5 LRFs were local and developed at the edge of the treatment field; the remaining 3 LRFs were in lymph nodes and occurred outside the treatment field. DMF developed in 12 patients (25%). The estimated 5-year cumulative incidences of LRF, DP, and DSD were 10%, 30%, and 21%, respectively. Acute toxicities included 5 episodes (10%) of grade 3 dermatitis and 1 episode (2%) of grade 3 mucositis. CONCLUSIONS. The authors report a site-specific series of patients with HN MCC who received RT. In this group of patients with adverse features, RT was well tolerated, and LRF was low. The propensity for MCC to recur at the edge of the treatment field suggests that generous margins are appropriate when RT is administered. Cancer 2012. © 2011 American Cancer Society. Adjuvant radiotherapy may benefit patients with Merkel cell carcinoma, which is a rare aggressive neuroendocrine tumor of the skin that is prone to high rates of locoregional failure and systemic progression. The authors report a site-specific series of head and neck Merkel cell carcinoma patients who received radiotherapy and observe that radiation is well tolerated and the rate of locoregional recurrence is low.

AB - BACKGROUND. The role of radiotherapy (RT) in the management of Merkel cell carcinoma (MCC) is controversial. The authors of this report evaluated the rates and patterns of failure in a selected group of patients who underwent RT for MCC of the head and neck (HN). METHODS. The records of 145 consecutive patients with MCC of the HN who presented to the authors' institution between 1988 and 2009 were reviewed. Only patients who received RT at the institution were included. The cumulative incidence of locoregional failure (LRF), distant metastatic failure (DMF), disease progression (DP) and disease-specific death (DSD) were estimated with death as a competing risk. RESULTS. Forty-eight patients were identified. The median follow-up was 51 months (range, 6-220 months) for living patients. LRF developed in 5 patients (10%), and those patients had a median time to recurrence of 3 months. Two of the 5 LRFs were local and developed at the edge of the treatment field; the remaining 3 LRFs were in lymph nodes and occurred outside the treatment field. DMF developed in 12 patients (25%). The estimated 5-year cumulative incidences of LRF, DP, and DSD were 10%, 30%, and 21%, respectively. Acute toxicities included 5 episodes (10%) of grade 3 dermatitis and 1 episode (2%) of grade 3 mucositis. CONCLUSIONS. The authors report a site-specific series of patients with HN MCC who received RT. In this group of patients with adverse features, RT was well tolerated, and LRF was low. The propensity for MCC to recur at the edge of the treatment field suggests that generous margins are appropriate when RT is administered. Cancer 2012. © 2011 American Cancer Society. Adjuvant radiotherapy may benefit patients with Merkel cell carcinoma, which is a rare aggressive neuroendocrine tumor of the skin that is prone to high rates of locoregional failure and systemic progression. The authors report a site-specific series of head and neck Merkel cell carcinoma patients who received radiotherapy and observe that radiation is well tolerated and the rate of locoregional recurrence is low.

KW - carcinoma

KW - head and neck

KW - Merkel cell

KW - neuroendocrine

KW - radiation

KW - radiotherapy

KW - recurrence

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84864666418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864666418&partnerID=8YFLogxK

U2 - 10.1002/cncr.26738

DO - 10.1002/cncr.26738

M3 - Article

C2 - 22180314

AN - SCOPUS:84864666418

VL - 118

SP - 3937

EP - 3944

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 16

ER -